R&D channel feed – Endpoints News

R&D channel feed

NuCana stops Phase 2 as chemotherapy derivative 'unlikely' to meet primary endpoint

8 months ago

Updated: Alnylam’s new Phase 3 ATTR data bring uncertainty to standard of care ambitions

8 months ago

Recursion nears ‘moment of truth’ with first key data, kicking off 18-month flurry of readouts

8 months ago

Merck ends two Phase 3 studies of Keytruda, including an early-stage non-small cell lung cancer trial

8 months ago

Preclinical team hit hardest in Repare's R&D prioritization, layoffs

8 months ago

UK government partners with pharma on new £400M life science infusion

8 months ago

Novartis seeks to expand Leqvio into heart disease prevention

8 months ago

Neurocrine's schizophrenia data are good enough for Phase 3 — but maybe not enough to beat Karuna

8 months ago

Bayer partners with RNA startup launched out of Dana-Farber

8 months ago

California Institute for Immunology and Immunotherapy gets $120M gift for vaccine, microbiome research

8 months ago

Pfizer partners with Flagship genetics startup Quotient on heart and kidney drugs

8 months ago

Once-promising cancer drugs appear to protect mice from Alzheimer’s

8 months ago

Invivyd says new Phase 3 data on Covid antibody support prophylactic use

8 months ago

Updated: Oculis closes Phase 3 eye drop trial due to 'administrative error' from third party

8 months ago

Swiss biotech's inhibitor of cancer driver shows promise in rare bleeding disorder

8 months ago

Once one of immuno-oncology's next great hopes, CD47 faces final shots on goal

8 months ago

Researchers downplay study that found a link between semaglutide and mental health

8 months ago

Jazz talking with Japan regulators about anti-seizure med Epidiolex after trial setback

8 months ago

Q&A: GSK CSO Tony Wood on staying out of obesity, 'careful' cancer ambitions, and AI's future in R&D

8 months ago

Timber Pharmaceuticals' candidate for rare skin disorder flunks all endpoints in late-stage trial

8 months ago

FDA rejects Regeneron’s multiple myeloma bispecific antibody over manufacturing issues

8 months ago

Dr. Reddy's and Stanford spinout Kainomyx partner up on anti-malarial program

8 months ago

Aadi says its solid tumor drug is unlikely to succeed, winding down the trial and axing staffers

8 months ago

Merck rejigs ADC deal with Kelun, grabbing one program and returning another

8 months ago

First page Previous page 28 29 303132 33 34 Next page Last page